Vivoryon Therapeutics N.V.
Registration details
Company overview
Vivoryon Therapeutics N.V. is a registered legal entity registered in Germany under HRB 29417 Stendal, and its current status with Handelsregister (Commercial Register) is active. The company was incorporated on 10 February 2021 and lists its registered address as Halle, Germany. No shareholders are recorded for Vivoryon Therapeutics N.V.; ownership in this jurisdiction is normally filed as the Gesellschafterliste (shareholder list) under §40 of the GmbHG, but no such filing is on record here. No beneficial owner record is shown for Vivoryon Therapeutics N.V., as access to the German Transparenzregister is restricted to obliged entities and legitimate-interest applicants following the November 2022 CJEU ruling. This profile is sourced directly from Handelsregister (Commercial Register) and was last updated on 25 September 2026.
Officers
13
Registry notes and limitations
Four of the 13 officer records shown for Vivoryon Therapeutics N.V. are current appointments, filed with Handelsregister (Commercial Register). Frank Thomas Weber, Anne Marie Doering and Michael Schaffer all serve as Managing Director; Florian Erich Schmid (appointed 2023-05-22) serves as Aufsichtsratsmitglied (board member). The remaining 9 records shown (Frank T. Weber M.d., Michael Karl Schaeffer and 7 others) are former appointments that have since been resigned.
The source filing doesn't specify representation authority — whether officers can act individually or must sign jointly to bind the company — so that detail isn't available here.
Frequently asked questions
Who is Vivoryon Therapeutics N.V.'s UBO (Ultimate Beneficial Owner)?
No Ultimate Beneficial Owner (UBO) record is shown for Vivoryon Therapeutics N.V., as access to the German Transparenzregister is restricted to obliged entities and legitimate-interest applicants following the November 2022 CJEU ruling.
What is Vivoryon Therapeutics N.V.'s company registration number?
Vivoryon Therapeutics N.V.'s registration number is HRB 29417 Stendal, filed with Handelsregister (Commercial Register) in Germany. Its current status on the register is active.
Is Vivoryon Therapeutics N.V. still an active company?
Vivoryon Therapeutics N.V.'s status on Handelsregister (Commercial Register) is listed as active.
When was Vivoryon Therapeutics N.V. incorporated?
Vivoryon Therapeutics N.V. was incorporated on 10 February 2021, according to Handelsregister (Commercial Register).
What is Vivoryon Therapeutics N.V.'s registered address?
The registered address on file for Vivoryon Therapeutics N.V. is Halle, Germany.
Who are the officers/directors of Vivoryon Therapeutics N.V.?
Four of the 13 officer records shown for Vivoryon Therapeutics N.V. are current appointments, filed with Handelsregister (Commercial Register). Frank Thomas Weber, Anne Marie Doering and Michael Schaffer all serve as Managing Director; Florian Erich Schmid (appointed 2023-05-22) serves as Aufsichtsratsmitglied (board member). The remaining 9 records shown (Frank T. Weber M.d., Michael Karl Schaeffer and 7 others) are former appointments that have since been resigned.
Can Zavia monitor changes to Vivoryon Therapeutics N.V.'s ownership over time?
This profile reflects a point-in-time snapshot from Handelsregister (Commercial Register). Zavia's monitoring API can track changes to Vivoryon Therapeutics N.V.'s registered shareholders, officers, and group structure going forward, flagging updates as they're filed rather than requiring a manual recheck.
Can I access Vivoryon Therapeutics N.V.'s data through an API?
Yes. Zavia's API connects directly to official government ownership registries across 195 countries and territories, including Germany, so records like Vivoryon Therapeutics N.V.'s registration, shareholder, UBO, and group-structure data can be queried programmatically instead of viewed one page at a time.
Where does this company information come from, and how current is it?
This record is sourced directly from Handelsregister (Commercial Register) and was last synced on 25 September 2026.